Drug Trial Radar · NCT07385547
Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency
Last checked: Nov 19, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Feb 25, 2026
Primary completion
Sep 2026
Study completion Sep 27, 2026
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries LimitedIndustry
- Sponsor type
- Industry
- First posted
- Feb 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label, single-dose, Phase 1 clinical study designed to evaluate the effect of renal impairment on the pharmacokinetics (PK) of GL0034, a long-acting GLP-1 receptor agonist. Approximately 40 adult participants will be enrolled across four groups: normal renal function, moderate renal impairment, severe renal impairment without dialysis, and severe renal impairment with dialysis. Each participant will receive a single subcutaneous dose of GL0034. Blood samples will be collected for PK analysis. Secondary objectives include assessing safety and tolerability. The study will help determine whether renal impairment affects GL0034 exposure and inform dosing recommendations for patients with compromised renal function.
Conditions
- Type II Diabetes Mellitus
Interventions
GL0034Drug
Subcutaneous (SC) administration of a single dose of GL0034
Primary outcomes
What the sponsor says the trial is designed to measure.
- Single dose PK exposure parameters: Maximum concentration (Cmax)Time frame: From predose through 672 hours post-dose (multiple time points)
- Single dose PK exposure parameters: Area under the plasma concentration-time curve (AUC) from time zero to the time of the last quantifiable concentration (AUC0-t)Time frame: From predose through 672 hours post-dose (multiple time points)
- Single dose PK exposure parameters: AUC from time zero extrapolated to infinite time (AUC0-i)Time frame: From predose through 672 hours post-dose (multiple time points)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Syneos Miami
Miami, Florida · Not yet recruiting
Panax Clinical Research
Miami Lakes, Florida · Recruiting
Orlando Clinical Research Center (OCRC)
Orlando, Florida · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.